REZILIENT3: Randomized Phase III Study of First-Line Zipalertinib Plus Chemotherapy in Patients with EGFR exon 20 Insertion-mutated NSCLC

Authors

John V Heymach
Helena A Yu
Benjamin Besse
Ying Cheng
Daniel Sw Tan
Li Wei
Volker Wacheck
Makoto Nishio

Language

English

Publication Date

2-1-2025

Journal

Future Oncology

DOI

10.1080/14796694.2025.2457294

PMID

39957151

PMCID

PMC11845107

PubMedCentral® Posted Date

2-16-2025

PubMedCentral® Full Text Version

Post-print

Abstract

There remains a significant unmet need for effective and tolerable treatments for patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (

Keywords

Adult, Aged, Female, Humans, Male, Middle Aged, Acrylamides, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Clinical Trials, Phase III as Topic, ErbB Receptors, Exons, Lung Neoplasms, Mutagenesis, Insertional, Mutation, Protein Kinase Inhibitors, Randomized Controlled Trials as Topic, EGFR, epidermal growth factor receptor, ex20ins, exon 20 insertions, non-small cell lung cancer, NSCLC, nonsquamous NSCLC, zipalertinib

Published Open-Access

yes

Recommended Citation

Heymach, John V; Yu, Helena A; Besse, Benjamin; et al., "REZILIENT3: Randomized Phase III Study of First-Line Zipalertinib Plus Chemotherapy in Patients with EGFR exon 20 Insertion-mutated NSCLC" (2025). Faculty, Staff and Student Publications. 5840.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/5840